ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-62534
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
0.5 mg/ml
Product Summary for ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody
Immunogen
Synthetic peptides corresponding to ASAHL The peptide sequence was selected from the middle region of ASAHL. Peptide sequence VSWLIRATLSESENFEAAVGKLAKTPLIADVYYIVGGTSPREGVVITRNR. The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Theoretical MW
37 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Description
The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Scientific Data Images for ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody
![Western Blot: ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody [NBP1-62534]](https://resources.bio-techne.com/images/products/ASAHL-N-acylethanolamine-hydrolyzing-Acid-Amidase-Antibody-Western-Blot-NBP1-62534-img0002.jpg "Western Blot: ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody [NBP1-62534]")
Western Blot: ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody [NBP1-62534]
Western Blot: ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody [NBP1-62534] - 721_B cell lysate, concentration 0.2-1 ug/ml.![Immunohistochemistry: ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody [NBP1-62534]](https://resources.bio-techne.com/images/products/ASAHL-N-acylethanolamine-hydrolyzing-Acid-Amidase-Antibody-Immunohistochemistry-NBP1-62534-img0003.jpg "Immunohistochemistry: ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody [NBP1-62534]")
Immunohistochemistry: ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody [NBP1-62534]
Immunohistochemistry: ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody [NBP1-62534] - Human Liver Tissue Observed Staining: Cytoplasm in lysosomes of hepatocytes Primary Antibody Concentration: 1 : 100 Other Working Concentrations: 1/600 Secondary Antibody: Donkey anti-Rabbit-Cy3 Secondary Antibody Concentration: 1 : 200 Magnification: 20XApplications for ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase
Alternate Names
Acid ceramidase-like protein, ASAH-like protein, NAAA, Nacylethanolaminehydrolyzing Acid Amidase
Gene Symbol
NAAA
UniProt
Additional ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Products
Product Documents for ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody
Product Specific Notices for ASAHL/N-acylethanolamine-hydrolyzing Acid Amidase Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...